MedPacto, Inc.
235980.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$102.31B
Close$
$1885.57
35.5% downside
Current Fair Value
35.5% downsideOvervalued by 35.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $102.31 Billion |
|---|---|
| Enterprise Value | $97.27 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-373.92 |
| Beta | 0.18 |
| Outstanding Shares | 34,275,121 |
Return
| Return on Equity | -35.78% |
|---|---|
| Return on Assets | -33.43% |
| Return on Invested Capital | -37.40% |
Valuation & Multiples
| P/E Ratio | -7.24 |
|---|---|
| PEG | -17.69 |
| Price to Sales | 20.17 |
| Price to Book Ratio | 2.54 |
| Enterprise Value to Revenue | 19.48 |
| Enterprise Value to EBIT | -6.41 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About MedPacto, Inc.
54 employees
CEO: Seong-Jin Kim MedPacto, Inc. is a South Korean biopharmaceutical company specializing in the research and development of novel therapeutic solutions for oncology and autoimmune conditions. The firm's pipeline includes several key drug candidates: ME-1...